10 April 2021: Clinical Research
Clinical Application of Chromosomal Microarray Analysis in Pregnant Women with Advanced Maternal Age and Fetuses with Ultrasonographic Soft Markers
Zhu-Ming Hu ABCE , Lei-Lei Li ABD , Han Zhang BF , Hong-Guo Zhang BC , Rui-Zhi Liu AFG , Yang Yu ACF*DOI: 10.12659/MSM.929074
Med Sci Monit 2021; 27:e929074
Table 2 Summary of the detection rates of CMA from pregnancies with AMA and fetuses with USG soft markers.
| All | Group 1 | Group 2 | Group 3 | |
|---|---|---|---|---|
| Number of cases | 1521 | 633 | 750 | 138 |
| Normal | 1191 (78.30%) | 504 (79.62%) | 592 (78.93%) | 95 (68.84%) |
| Abnormal | 330 (21.70%) | 129 (20.38%) | 158 (21.07%) | 43 (31.16%) |
| Clinical significant | 37 (2.43%) | 15 (2.37%)* | 15 (2.00%)** | 7 (5.07%),* |
| VOUS | 240 (15.78%) | 93 (14.69%) | 120 (16.0%) | 27 (19.57%) |
| Benign or likely benign | 52 (3.42%) | 20 (3.16%) | 23 (3.07%) | 9 (6.52%) |
| Mosaic | 1 (0.07%) | 1 (0.16%) | 0 (0.00%) | 0 (0.00%) |
| CMA – chromosomal microarray analysis; AMA – advanced maternal age; VOUS – variants of unknown significance. * Clinically significant CNVs by CMA in Group 1 versus Group 3: p ** Clinically significant CNVs by CMA in Group 2 versus Group 3: p | ||||